

A two-sex model of human papillomavirus infection: Vaccination strategies and a case study

Shasha Gao^a, Maia Martcheva^{a,*}, Hongyu Miao^b, Libin Rong^{a,*}

^a*Department of Mathematics, University of Florida, Gainesville, FL 32611*

^b*Department of Biostatistics and Data Science, University of Texas Health Science Center at Houston, TX 77030*

Abstract

Vaccination is effective in preventing human papillomavirus (HPV) infection. It still remains debatable whether males should be included in a vaccination program and unclear how to allocate the vaccine in genders to achieve the maximum benefits. In this paper, we use a two-sex model to assess HPV vaccination strategies and use the data from Guangxi Province in China as a case study. Both mathematical analysis and numerical simulations show that the basic reproduction number, an important indicator of the transmission potential of the infection, achieves its minimum when the priority of vaccination is given to the gender with a smaller recruit rate. Given a fixed amount of vaccine, splitting the vaccine evenly usually leads to a larger basic reproduction number and a higher prevalence of infection. Vaccination becomes less effective in reducing the infection once the vaccine amount exceeds the smaller recruit rate of the two genders. In the case study, we estimate the basic reproduction number is 1.0333 for HPV 16/18 in people aged 15-55. The minimal bivalent HPV vaccine needed for the disease prevalence to be below 0.05% is 24050 per year, which should be given to females. However, with this vaccination strategy it would require a very long time and a large amount of vaccine to achieve the goal. In contrast with allocating the same vaccine amount every year, we find that a variable vaccination strategy with more vaccine given in the beginning followed by less vaccine in later years can save time and total vaccine amount. The variable vaccination strategy illustrated in this study can help to better distribute the vaccine to reduce the HPV prevalence. Although this work is for HPV infection and the case study is for a province in China, the model, analysis and conclusions may be applicable to other sexually transmitted diseases in other regions or countries.

Keywords: HPV, two-sex, deterministic model, vaccination strategy, sexually transmitted diseases

*Correspondence should be addressed to M. Martcheva (maia@ufl.edu) or L. Rong (libinrong@ufl.edu).

1. Introduction

Human papillomavirus (HPV) is mainly transmitted through sexual contact. There are more than 100 types of HPV, among which at least 14 can cause cancer and are known as high risk types. Almost all sexually active people are infected at some point in their lives and some may be repeatedly infected. HPV infections usually clear up without any intervention within a few months after acquisition, and about 90% will clear within 2 years. However, in some cases, HPV infection can persist and progress to cancer [1]. Cervical cancer is the most common HPV-related cancer in women, with an estimated 569,847 new cases and 311,365 deaths in 2018 globally. There is some evidence linking HPV infection with other cancers of vulva, anus, vagina, penis and oropharynx. In the high risk type group, HPV 16/18 cause 70% of cervical cancers and pre-cancerous cervical lesions. In the low risk type family, HPV 6/11 result in 90% of genital warts and most RRP (recurrent respiratory papillomatosis) [1].

Vaccination is an effective way to prevent HPV infection. There are currently 3 prophylactic vaccines available. The bivalent, quadrivalent and 9-valent vaccine protect people from HPV types 16/18, 16/18/6/11 and 16/18/6/11/31/33/45/52/58, respectively. HPV vaccines have been shown to be safe and very effective in preventing HPV infection and its sequelae [2, 3]. HPV vaccine works more effectively if injected before potential exposure to HPV. Therefore, the World Health Organization (WHO) recommends to vaccinate girls aged 9-14 [1]. By October 2019, more than 100 countries have introduced HPV vaccines to their national schedules [4]. In many countries, HPV vaccines are only offered to pre-adolescent girls (may also include catch-up programs for older females). An increasing number of countries such as Australia, the US and UK also recommend HPV vaccines to pre-adolescent boys and young men, including men who have sex with men (MSM) [5–7]. However, due to the shortage of HPV vaccines, the WHO has called for countries to suspend vaccination of boys in December, 2019 [8]. There has been a long-standing debate about offering HPV vaccines to boys. Without vaccinating boys, health benefits brought from vaccine would not be maximized [9]. However, a few transmission dynamic models showed that strong herd effects were expected from girls-only policy, even with coverage as low as 20% [10]. Should boys be included in a vaccination program? How to allocate HPV vaccines available in a place to maximize the benefit? These questions need to be further investigated.

During the past two decades, a number of mathematical models have been developed to study the epidemiological and economic consequences of HPV vaccination. Elbasha et al. constructed a dynamic model including both demographic and epidemiologic components to assess the epidemiologic consequences and cost-effectiveness of quadrivalent HPV vaccination strategies [11]. They found that vaccinating girls and women was cost-effective and including men and boys was the most effective strategy. Using a similar model, they showed that the quadrivalent HPV vaccines would be cost-effective when administered to females aged 12-24 years or to both females and males before age 12 with a 12-24 years of age catch-up program [12]. By updating the above two models, Elbasha and his collaborator concluded that expanding the current quadrivalent HPV vaccines to boys and men aged 9-26 could provide tremendous public health benefits and was also cost-effective in the United States [13].

41 The models from ref. [11–13] provided a framework, on which more mathematical model have
42 been developed to study HPV infection and vaccination [14–20]. For example, Insinga et al. found
43 the most effective strategy for quadrivalent HPV vaccines in Mexico was vaccinating 12 years old
44 children plus a temporary 12-24 years old catch-up program covering both sexes [14]. Gender-
45 neutral program was also considered to be a cost-effective choice in France and Italy [17, 21]. On
46 the other hand, there are several studies concluding that girls-only program is more cost-effective
47 [16, 22–25]. For instance, Cody et al. compared different vaccination strategies of 4-valent or 9-
48 valent HPV vaccines in Japan. They found that the most cost-effective strategy was the vaccination
49 program with 9-valent vaccine targeting 12-16 years old girls together with a temporary catch-up
50 program [16]. Similarly, Kim et al. showed that increasing the coverage in girls was more effective
51 and less costly than including boys in a low-resource setting [22]. Damm et al. found that the
52 cost-effectiveness of additional vaccination for boys was highly dependent on the coverage in girls
53 [26].

54 Some other papers investigated the impact of HPV vaccines and proper vaccine distributions
55 without considering cost-effectiveness [27–45]. Several of them suggested that girls-only policy
56 was better than including boys, at least in the present situation [27–31]. Vaccinating boys was only
57 reasonable if the vaccination coverage for girls was moderate or high [33]. Brisson et al. found
58 that the benefit of vaccinating boys decreased as the coverage in girls increased [30]. However,
59 Azevedo et al. showed that without including men in a vaccination program the disease could only
60 be controlled when more than 90% of women were vaccinated [32]. Muñoz-Quiles et al. con-
61 structed a computational network model and found that HPV-related diseases in women would be
62 eliminated within five decades if the vaccine coverage can achieve 75% for both females and males
63 [44]. In addition, Bogaards et al. found that giving vaccines to the gender with the highest pre-
64 vaccine prevalence would most reduce the prevalence [28]. Waning immunity was also considered
65 to be important, especially when studying persistent HPV infection and its associated cancer in-
66 cidence [31, 34]. The impact of HPV vaccination was also evaluated in the population of MSM
67 [27, 44–46]. Díez-Domingo et al. showed that MSM would not benefit by the herd immunity effect
68 of vaccinating females [46]. In our previous paper [27], we found that the heterosexual population
69 gets great benefit but MSM only get minor benefit from vaccinating heterosexual females or males.
70 The priority of vaccination should be given to MSM in order to eliminate HPV infection, especially
71 in places that have already achieved high coverage in females.

72 Most of the above studies obtained the results on vaccine distribution either from cost-effectiveness
73 analysis or numerical simulations, without providing analytical results. In this paper, we will use a
74 two-sex deterministic model to analytically investigate the vaccine distribution strategy. Using the
75 data from Guangxi Province in China as a case study, we will study what strategies would save time
76 and the total amount of vaccines. Specifically, we will mainly address the following questions: 1.
77 Given a fixed vaccine amount, what is the best way to split the vaccines between the two genders
78 to reduce HPV prevalence? 2. In the case study, what is the threshold of vaccine amount needed
79 to eliminate HPV infection? 3. To reduce HPV prevalence to below a certain threshold, how many
80 years and how many total vaccines are needed under different strategies? How to best allocate these
81 vaccines? To answer these questions, we will formulate and analyze the model in Section 2 and

82 3, respectively. We conduct a variety of simulations on different vaccine distribution strategies in
83 Section 4. Some discussions of the results follow in Section 5.

84 2. Model formulation

85 In this section, we formulate a two-sex deterministic model to study the transmission of HPV
86 infection in a heterosexually active population. The population is divided into two groups, namely,
87 heterosexual females and heterosexual males (for simplicity, we will use females and males below),
88 and subscripts f and m are used to denote them. In each group, the population is divided into 3
89 classes: susceptible (S_k), vaccinated (V_k) and infected individuals (I_k), where $k \in \{f, m\}$.

90 In the absence of vaccination, we assume that humans become sexually active and enter the
91 susceptible compartment S_k with the recruitment rate Λ_k . They leave a compartment at a rate μ_k .
92 Susceptible individuals are infected by HPV with the force of infection λ_k . Upon infection, the host
93 moves to the infected compartment I_k . Infected people can clear infection at a rate δ_k . Although
94 natural recovery can provide protection against future infection for many other virus infections,
95 the situation for HPV might be different. Several studies found that HPV reinfection is common
96 for both females and males, even with the same HPV type [47, 48]. Therefore, in this paper
97 we formulate a deterministic model based on the SIS (susceptible-infected-susceptible) structure,
98 which was also used in some other HPV modeling studies such as ref. [25, 37]. We will discuss
99 the potential influence of adopting a different model, e.g. SIR (susceptible-infected-recovered), on
100 our results.

101 In the model with vaccination, we assume that a fraction (ϕ_k) of susceptibles are vaccinated
102 and vaccine-induced immunity does not wane during the sexually active period. Vaccine offers a
103 degree of protection τ ($0 \leq \tau \leq 1$) regardless of gender. Thus, the probability of a vaccinated
104 person getting infected and moving to the infected compartment I_k is $1 - \tau$. We also assume that
105 all infected individuals, vaccinated or not, can clear infection and become susceptible at a rate δ_k .
106 The model is described by the following system of ordinary differential equations. A schematic
107 diagram of the model is shown in Figure 1.

$$\begin{cases} S'_k(t) = (1 - \phi_k)\Lambda_k - \lambda_k S_k + \delta_k I_k - \mu_k S_k \\ V'_k(t) = \phi_k \Lambda_k - (1 - \tau)\lambda_k V_k - \mu_k V_k \\ I'_k(t) = \lambda_k [S_k + (1 - \tau)V_k] - (\delta_k + \mu_k)I_k \end{cases} \quad (1)$$

The force of infection is given by

$$\lambda_k = \frac{\beta_{k'k} I_{k'}}{N_k},$$

108 where $N_k = S_k + V_k + I_k$, $k, k' \in \{f, m\}$ and $k \neq k'$. The total population is $N = N_f + N_m$.

Taking the sum of S_k , V_k and I_k in system (1), we get $N'_k = \Lambda_k - \mu_k N_k$, $k = f, m$. Thus, the equilibrium of N_k is Λ_k/μ_k . We define the domain of the system (1) to be

$$D = \{(S_f, V_f, I_f, S_m, V_m, I_m) \in \mathfrak{R}_+^6 : S_k + V_k + I_k \leq \Lambda_k/\mu_k, k = f, m\}.$$

109 Using a similar method in the previous study [27], we can verify that D is positively invariant for
 110 system (1) and the model is both epidemiologically and mathematically well posed.

111 3. Analysis of the model

112 3.1. The model without vaccination

113 The model (1) without vaccination reduces to

$$\begin{cases} S'_k(t) = \Lambda_k - \lambda_k S_k + \delta_k I_k - \mu_k S_k, \\ I'_k(t) = \lambda_k S_k - (\delta_k + \mu_k) I_k. \end{cases} \quad (2)$$

The force of infection is given by

$$\lambda_k = \frac{\beta_{k'k} I_{k'}}{N_k},$$

114 where $N_k = S_k + I_k$, with $k, k' \in \{f, m\}$ and $k \neq k'$.

We define

$$R_{0,mf} = \frac{\beta_{mf}}{\delta_m + \mu_m}, \quad R_{0,fm} = \frac{\beta_{fm}}{\delta_f + \mu_f}.$$

$R_{0,mf}$ represents the number of secondary female infections generated by one infectious male in an entirely susceptible female population during his whole infectious period. $R_{0,fm}$ has similar meaning. Using the next generation approach [49], we derive the basic reproduction number to be

$$R_0 = \sqrt{R_{0,mf} R_{0,fm}}.$$

115 It represents the number of secondary infections generated by one infectious individual in an en-
 116 tirely susceptible population during the whole infectious period of the individual.

117 The system (2) always has a disease-free equilibrium (DFE) $E^0 = (\Lambda_f/\mu_f, 0, \Lambda_m/\mu_m, 0)$. Its
 118 local stability is stated in Theorem 1. We present the global stability of the limiting system in
 119 Theorem 2. Their proofs are given in Appendix A and B, respectively.

120 **Theorem 1.** When $R_0 < 1$, the DFE E^0 is locally asymptotically stable; when $R_0 > 1$, the DFE E^0
 121 is unstable.

122 **Theorem 2.** When $R_0 \leq 1$, the DFE E^0 is globally asymptotically stable.

123 By setting the right-hand side of system (2) to zero, we can solve for the endemic equilibrium,
 124 which is shown in Theorem 3. Its local stability is stated in Theorem 4. The global stability of the
 125 limiting system is given in Theorem 5. The proofs of Theorem 4 and 5 are given in Appendix C
 126 and D, respectively.

Theorem 3. When $R_0 > 1$, there exists a unique endemic equilibrium $E^* = (S_f^*, I_f^*, S_m^*, I_m^*)$, where

$$S_k^* = \frac{N_{k'}^*(\delta_{k'} + \mu_{k'}) + N_k^* \beta_{kk'}}{d_k N_{k'}^*(\delta_{k'} + \mu_{k'})}, \quad I_k^* = \frac{R_0^2 - 1}{d_k}, \quad d_k = \frac{R_0^2}{N_k^*} + \frac{\beta_{kk'}}{N_{k'}^*(\delta_{k'} + \mu_{k'})},$$

127 with $N_k^* = \Lambda_k/\mu_k$, $k, k' \in \{f, m\}$, $k \neq k'$.

128 **Theorem 4.** When $R_0 > 1$, the endemic equilibrium E^* is locally asymptotically stable.

129 **Theorem 5.** When $R_0 > 1$, the endemic equilibrium E^* is globally asymptotically stable.

130 3.2. The model with vaccination: Analysis and best vaccination strategy

In this section, we study model (1) with vaccination. Similar to the model without vaccination, we define

$$R_{0,mf}(\phi_f) = \frac{\beta_{mf}}{\delta_m + \mu_m} [(1 - \phi_f) + (1 - \tau)\phi_f],$$
$$R_{0,fm}(\phi_m) = \frac{\beta_{fm}}{\delta_f + \mu_f} [(1 - \phi_m) + (1 - \tau)\phi_m].$$

Using the next generation approach, we derive the basic reproduction number to be

$$R_0(\phi_f, \phi_m) = \sqrt{R_{0,mf}(\phi_f)R_{0,fm}(\phi_m)}.$$

131 When $\phi_f = \phi_m = 0$, it is the same as the basic reproduction number for the model without vaccina-
132 tion.

The system (1) always has a disease-free equilibrium

$$E^0 = \left((1 - \phi_f) \frac{\Lambda_f}{\mu_f}, \phi_f \frac{\Lambda_f}{\mu_f}, 0, (1 - \phi_m) \frac{\Lambda_m}{\mu_m}, \phi_m \frac{\Lambda_m}{\mu_m}, 0 \right).$$

133 Its local stability is stated in Theorem 6. The proof is similar to Theorem 1 and is omitted. Due to
134 the complexity of the model, it is hard to study the global stability for the DFE. However, using a
135 similar method as in ref. [27], we can show that there is no backward bifurcation for system (1).
136 For the endemic equilibrium, we have the result for its existence, which is stated in Theorem 7 and
137 proved in Appendix E.

138 **Theorem 6.** When $R_0(\phi_f, \phi_m) < 1$, the DFE E^0 is locally asymptotically stable; when $R_0(\phi_f, \phi_m) >$
139 1 , the DFE E^0 is unstable.

140 **Theorem 7.** When $R_0(\phi_f, \phi_m) > 1$, the endemic equilibrium exists.

From the above analysis, we know that the condition $R_0 < 1$ is critical for disease elimination. R_0 is also an important indicator that quantifies how fast the disease spreads. Therefore, given a fixed vaccine amount v , we investigate the following optimization problem

$$\begin{cases} \text{minimize } R_0(\phi_f, \phi_m) \\ \text{subject to } 0 \leq \phi_f \leq 1, 0 \leq \phi_m \leq 1, \phi_f \Lambda_f + \phi_m \Lambda_m = v, \end{cases}$$

141 where $0 \leq v \leq \Lambda_f + \Lambda_m$. The result is stated in the following Theorem and the proof is given in
142 Appendix F.

143 **Theorem 8.** (i) If $\Lambda_k \leq \Lambda_{k'}$, then $\min R_0(\phi_f, \phi_m)$ is attained at $\phi_k = \frac{v}{\Lambda_k}, \phi_{k'} = 0$ when $v \leq \Lambda_k$ and
144 $\phi_k = 1, \phi_{k'} = \frac{v - \Lambda_k}{\Lambda_{k'}}$ when $v > \Lambda_k$. Here $k, k' \in \{f, m\}$ and $k \neq k'$.
145 (ii) When $\Lambda_f = \Lambda_m = \Lambda$, the smaller $|\phi_f - \phi_m|$, the bigger $R_0(\phi_f, \phi_m)$. An even distribution (i.e.
146 $\phi_f = \phi_m = \frac{v}{2\Lambda}$) leads to $\max R_0(\phi_f, \phi_m)$.

147 The above Theorem shows that to minimize the basic reproduction number R_0 , the gender with
148 a smaller recruit rate should be vaccinated with priority. If there is vaccine left, it will be given to
149 the other gender. When the two genders have the same recruit rate, splitting vaccines evenly is the
150 worst, i.e. resulting in the maximum R_0 . The evener the distribution, the bigger R_0 .

151 For convenience, we consider $\min R_0^2$ as a function of v and denote it by $h(v)$. We have the
152 following result with the proof given in Appendix G.

153 **Corollary 1.** (i) $h'(v) < 0$ always holds.
154 (ii) If $\Lambda_k \leq \Lambda_{k'}$, $|h'(v)|$ is larger when $v \leq \Lambda_k$ than that when $v > \Lambda_k$, where $k, k' \in \{f, m\}$ and $k \neq k'$.
155 This Corollary shows that as the vaccine amount v increases, the minimum of the basic repro-
156 duction number R_0 decreases. Once the vaccine amount exceeds the smaller recruit rate of the two
157 genders, vaccination becomes less effective in reducing the basic reproduction number.

158 4. Vaccination strategies and a case study

159 4.1. Calibration of transmission rates

160 In this section, we use the data from Guangxi Province in China to calibrate parameter values
161 used in the model. We will investigate various vaccination strategies on the basis of these parameter
162 values. We determine the transmission rates of HPV 16/18 in the model without vaccination.
163 In 2014, an observational cohort study including 2309 men and 2378 women aged 18-55 was
164 conducted in Liuzhou, Guangxi Province (in the end, 1937 men and 2344 women were included
165 in the analysis). Therefore, we set $\mu_f = \mu_m = \frac{1}{55-18}$. The median time (95% CI) to clear HPV
166 16/18 is 12.3 [7.7, 13.3] months for females and 6.5 [6.2, 7.7] months for males [50]. So we let the
167 recovery rates (95% CI) for females and males be $\delta_f = 12/12.3$ [12/13.3, 12/7.7] and $\delta_m = 12/6.5$
168 [12/7.7, 12/6.2] with unit 1/year, respectively.

The prevalences of HPV 16/18 for females and males are $p_f = 107/2344 = 4.6\%$ and
 $p_m = 30/1937 = 1.5\%$, respectively [51]. According to Liuzhou Statistical Yearbook [52], there
were 2411020 people aged 18-60 in Liuzhou in 2014, and the total female and male populations
are 1817723 and 1961637, respectively. Hence the female and male populations aged 18-55 are
estimated as

$$N_f^* = 2411020 \times \frac{55 - 18}{60 - 18} \times \frac{1817723}{1817723 + 1961637} = 1.0216 \times 10^6$$

and

$$N_m^* = 2411020 \times \frac{55 - 18}{60 - 18} \times \frac{1961637}{1817723 + 1961637} = 1.1024 \times 10^6.$$

Since HPV infection had existed in Liuzhou for many years before 2014 and HPV vaccine was available until 2016 in mainland China, we assume that HPV infection was in the endemic state at that time. From the expression of the endemic equilibrium of the model without vaccination, we get

$$p_f = \frac{I_f^*}{N_f^*} = \frac{\frac{\beta_{mf}\beta_{fm}}{(\delta_f + \mu_f)(\delta_m + \mu_m)} - 1}{\frac{\beta_{mf}\beta_{fm}}{(\delta_f + \mu_f)(\delta_m + \mu_m)} + \frac{N_f^*}{N_m^*} \frac{\beta_{fm}}{\delta_m + \mu_m}},$$

$$p_m = \frac{I_m^*}{N_m^*} = \frac{\frac{\beta_{mf}\beta_{fm}}{(\delta_f + \mu_f)(\delta_m + \mu_m)} - 1}{\frac{\beta_{mf}\beta_{fm}}{(\delta_f + \mu_f)(\delta_m + \mu_m)} + \frac{N_m^*}{N_f^*} \frac{\beta_{mf}}{\delta_f + \mu_f}}.$$

169 With the above values, we get the transmission rates (95% CI) from females to males is $\beta_{mf} =$
 170 2.8693 [2.6594, 4.5373] and from males to females is $\beta_{fm} = 0.6967$ [0.5896, 0.7299].

171 4.2. Parameter setting

172 We apply the model to Guangxi province with a wider range of ages 15 – 55. Hence $\mu_f = \mu_m =$
 173 $\frac{1}{55-15}$. There are two reasons for using a wider age range. One is that some people have sex at
 174 young ages (before age 18). The other is that we are interested in the number of target vaccination
 175 population (i.e. 14-year-old children) and want to roughly use it as recruits. The values for $\delta_f,$
 176 δ_m, β_{mf} and β_{fm} are the same as above. We estimate the number of 14-year-old boys and girls
 177 in Guangxi in 2021-2033 (Figure 2, for details see Appendix H), which are the target vaccination
 178 groups. We find that there are only minor changes for both 14-year-old boys and girls from 2021-
 179 2033. Therefore, we use the average number as the recruitment rate, namely, $\Lambda_f = 340998$ and
 180 $\Lambda_m = 387463$. Applying all these values to the expression of R_0 without vaccination, we derive that
 181 the basic reproduction number for HPV 16/18 within the age group 15-55 in Guangxi is 1.0333.
 182 Using type-specific and gender-specific clearance rate and prevalence derived from ref. [50, 51],
 183 we get basic reproduction numbers for some other HPV types (Table 2).

184 Chinese domestic bivalent HPV vaccine has been available in Guangxi since 2020. We apply
 185 the bivalent HPV vaccine in our model. The value (range) for vaccine efficacy τ is 0.899 [0.817-
 186 0.944] for HPV 16/18 [53]. So far the bivalent HPV vaccine is only available to females in China.
 187 Using all the above values in $R_0(\phi_f, \phi_m)$ and setting $\phi_m = 0$ and $R_0(\phi_f, \phi_m) = 1$, we calculate the
 188 critical value of ϕ_f for HPV 16/18 elimination is $\hat{\phi}_f = 0.0705$. The corresponding vaccine amount
 189 is $\hat{v} = \hat{\phi}_f \Lambda_f = 24050$.

190 4.3. Sensitivity analysis

191 We use the partial rank correlation coefficient (PRCC) to evaluate the impact of model pa-
 192 rameters on the dynamics of the model (1). The PRCC provides a global sensitivity analysis for
 193 nonlinear but monotone relationships between inputs and outputs [54]. From analytical results,

194 we know that $R_0 < 1$ is essential to eliminate the disease. Therefore, we are concerned with the
195 parameters that have the greatest impact on R_0 . We are also interested in the parameters that have
196 great impact on the prevalence. Therefore, in our sensitivity analysis, the inputs are parameters and
197 the outputs are R_0 , the prevalence in females, males and the total population. In the inputs, there is
198 a special parameter called dummy, which is introduced to quantify the artifacts (for details see ref.
199 [54]).

200 In the sensitivity analyses, we choose the vaccination proportion $\phi_f = 0.08$ and $\phi_m = 0.01$ as
201 baseline values and $[0.01, 0.99]$ as their ranges. Since we only focus on people in the age group
202 15-55, we fix $\mu_f = \mu_m = 1/(55 - 15)$ and use one parameter μ to represent them. The sample
203 size for R_0 is 10000, and for each prevalence is 6000. The initial condition for the prevalence
204 is pre-vaccination endemic equilibrium, and the end point is 50 years. The negative or positive
205 sign of the PRCC value indicates that the parameter is inversely or positively correlated with the
206 outputs. The parameter with a larger PRCC index (absolute value greater than 0.5) has more
207 significant influence on the output [55]. From Figure 3 and Table 3, we see that the proportions of
208 vaccination ϕ_f and ϕ_m always have a great impact on the basic reproduction number and the disease
209 prevalence. This means that vaccination is an effective way to reduce HPV infection. The output
210 is also sensitive to the clearance rates δ_f and δ_m . This indicates that infected individuals having an
211 intact immune response or receiving treatment have a better chance to clear the infection. Other
212 sensitive parameters include transmission rates β_{mf} and β_{fm} , which highlights the importance of
213 using condom or other protections to reduce the risk of infection.

214 4.4. The best vaccination strategy

215 The condition $R_0 < 1$ is critical for disease elimination. We are interested in the minimum
216 vaccine amount needed per year to hit this threshold. Using linear programming, we find that
217 this value is 24050, which is attained when all vaccines are given to girls (Figure 4(a)(b)). It
218 agrees with the results in Section 4.2. To verify that this is a critical value and giving vaccines
219 to girls is better, we set $v = 25000$, which is slightly bigger than the above threshold. We can
220 see $\min R_0 = 0.9987 < 1$, which is obtained when all vaccines are given to girls (Figure 4(c)).
221 In this case all prevalences in females, males and the total population go to zero. They decline
222 faster than when we give all vaccines to boys or split them evenly (Figure 4(d)-(f)). These results
223 are also consistent with the analysis. More specifically, because $\Lambda_f < \Lambda_m$ in the case study,
224 vaccinating females firstly results in a smaller R_0 , which leads to a lower prevalence. Interestingly,
225 even for males, vaccinating girls firstly is still better (see Figure 4(e)). This is reasonable because
226 the transmission always involves both genders. Since Figure 4(d)-(f) show that the dynamics of
227 prevalence in females, males and the total population are similar, from now on we will only focus
228 on the prevalence in the total population.

229 From Figure 4(f) we also notice that although the disease will go extinct eventually, it will take
230 more than 1000 years and the total vaccine needed will be more than $25000 \times 1000 = 2.5 \times 10^7$.
231 A critical question arises: can we find a better vaccination strategy requiring less time and less
232 total vaccine amount? Figure 5 shows some vaccination strategies that need less time and less total

233 vaccine amount. Comparing these cases, we estimate that some value $\nu \in [50000, 150000]$ will
234 result in the smallest total vaccine amount.

235 To further address the above question, we compare the prevalence in the total population for
236 different values of ν by vaccinating girls firstly (Figure 6). We set a specific threshold 0.0005 for
237 the prevalence in the total population, and compute the total time and total vaccine amount needed
238 to reach this threshold (Table 4). We find that allocating 60000 vaccine shots per year leads to the
239 smallest total vaccine amount (6205014) among these cases. It will take about 103 years to achieve
240 this goal.

241 From Figure 6, we also notice that for any fixed vaccine amount ν , the prevalence decreases
242 at different speed during different time periods. This indicates that the efficacies of reducing the
243 prevalence with the same amount of vaccine are different. Therefore, we consider variable vaccine
244 amount for different time periods. In Figure 7 (a) we consider three vaccination strategies, namely,
245 adjusting vaccine amount every 50 years, every 30 years and every 20 years. We compare them with
246 the fixed vaccine amount $\nu = 60000$ per year. Table 5 shows that all the three variable vaccination
247 strategies need less time and less total vaccine amount.

248 Furthermore, we consider vaccination with more frequent adjustments. We find strategies with
249 even less time and less total vaccine amount (Table 6). If we allocate 175000 vaccine amount per
250 year in the first 5 years and reduce by 15000 every 5 years, then it only takes about 58 years to
251 achieve our goal and the total vaccine amount is 5225000. If we apply this strategy and consider
252 cross protection of bivalent HPV vaccines for other HPV types, Figure 7 (b) shows the prevalence
253 in the total population for HPV types covered by 9-valent HPV vaccine in the next 60 years.

254 Now we consider another case in which there are sufficient HPV vaccines. How to reduce the
255 prevalence in the total population as soon as possible? If we only consider vaccinating adolescent
256 girls, which is the main target population recommended by the WHO, the best situation is that all
257 girls are vaccinated before age 15, namely, $\phi_f = 1$ and $\phi_m = 0$. In this case, it will take about
258 27 years to reduce the prevalence in the total population to below 0.0005 (Figure 8 (a)) and the
259 total vaccine amount is 9231805. For a fixed vaccine amount, although vaccinating girls firstly is
260 better, vaccinating boys is still helpful in reducing the prevalence. For example, if we vaccinate
261 all 14-year-old girls and boys every year, then it will take about 19 years to reduce the prevalence
262 in the total population to below 0.0005 (Figure 8 (a)). However, the total vaccine amount is much
263 higher (13895612) in this case. In practice, it is not realistic to achieve 100% coverage. Therefore,
264 we consider more cases with different coverages in Table 7 and Figure 8 (a). We see that a higher
265 vaccine coverage in females and males leads to a smaller R_0 and it takes a shorter time to reduce
266 the prevalence to below 0.0005.

267 Catch-up vaccination (i.e. vaccinate older people) is also useful in reducing the prevalence,
268 especially in the beginning when HPV vaccines are introduced. For example, we assume that α is
269 the proportion of women getting catch-up vaccination. Combining with vaccinating all adolescent
270 girls before they become susceptible, the model predicts that the time needed to reduce the preva-
271 lence in the total population to below 0.0005 is 20 years when $\alpha = 0.02$ and 13 years when $\alpha = 0.1$
272 (Figure 8 (b)).

273 5. Discussion

274 In this paper, we developed a two-sex deterministic model to evaluate the epidemiological
275 impact of HPV vaccination in a heterosexually active population. We derived the basic production
276 number R_0 and studied the stability of equilibria. The analysis shows that R_0 plays a critical role in
277 predicting how the infection spreads. The smaller R_0 , the lower prevalence in the total population.
278 In order to reduce R_0 , given a fixed vaccine amount, we investigated how to allocate vaccines
279 between the two genders. By rigorous mathematical analysis, we found that $\min R_0$ is achieved
280 when vaccinating the gender with a smaller recruit rate firstly and giving the remaining vaccines,
281 if left, to the other gender. This was numerically illustrated by a case study in which there are
282 fewer female recruits in Guangxi. Vaccinating girls firstly results in the smallest R_0 and lowest
283 prevalence in the total population compared to other strategies. We also considered a special case
284 in which the recruits for females and males are the same. In this case, besides the same conclusion
285 for $\min R_0$, we also found allocating vaccines evenly leads to $\max R_0$. The evener the distribution,
286 the bigger R_0 , consequently the higher prevalence. We also proved that $\min R_0$ decreases as the
287 vaccine amount v increases but vaccination becomes less effective once its amount exceeds the
288 smaller recruit rate.

289 The above conclusion on vaccine distribution is reasonable because given a fixed vaccine
290 amount, vaccinating the gender that has a smaller recruit rate enables a larger proportion of the
291 population of that gender getting vaccinated. This leads to more reduction in R_0 and the preva-
292 lence in the total population. In a previous paper studying vaccination in a heterosexual population
293 and MSM [27], we assumed the same recruit rate for heterosexual females and males. We found
294 that vaccinating either gender firstly leads to the same prevalence in the total population and this
295 prevalence is lower than splitting vaccines evenly. This agrees with the conclusion here. Bogaards
296 et al. found that vaccinating the gender with a higher pre-vaccination prevalence would result in
297 a larger reduction of the population prevalence [28]. This is also consistent with our result as a
298 higher pre-vaccination prevalence means more people had already gained immunity. Thus, keep-
299 ing vaccinating that gender will result in a larger proportion of people getting protected. Some
300 other papers also suggested that increasing the vaccine coverage in girls was better than including
301 boys [29–31]. In other words, they also aimed to get a bigger proportion of people protected within
302 the same gender. This strategy indicates that high coverage in one gender can provide strong herd
303 immunity for sexually transmitted diseases, which also agrees with the results in refs. [44, 45].

304 Using data from Liuzhou, a city in Guangxi province, we calibrated the transmission rates β_{mf}
305 and β_{mf} . We calculated the basic reproduction number $R_0 = 1.0333$ for HPV 16/18 in people aged
306 15-55. Using the estimated recruits in Guangxi, we predicted that the minimum number of bivalent
307 HPV vaccine shots is 24050, which should be given to girls. We also derived basic reproduction
308 numbers for some other HPV types. There are few studies in the literature providing estimates
309 of the basic reproduction number for other HPV types. Riesen et al. estimated that R_0 for HPV
310 16 in Switzerland was 1.29 [56], and Ribassin-Majed et al. calculated R_0 for HPV 6/11 in France
311 to be 1.04 [37]. The difference in these estimates could be caused by different assumptions. For
312 example, we adopted the gender-specific clearance rate from data, and the other two models used

313 the same clearance rate for both genders. Social and sexual behaviors may also affect the disease
314 spread. Ziyadi et al. obtained a very small basic reproduction number ($R_0 = 0.2346$) for the African
315 American population [38]. One possible explanation is that the authors used the fitted recruitment
316 and relatively small infection rates.

317 Although HPV infection is predicted to go extinct once the vaccine amount exceeds a critical
318 value, it would take a very long time and the total vaccine amount could be huge. To find a better
319 vaccination strategy, namely, within a shorter period of time and with less total vaccine amount,
320 we set a specific goal, i.e., the prevalence in the total population is less than 0.05%. We compared
321 several strategies and found that the one offering 60000 vaccine shots to girls every year resulted in
322 the smallest total vaccine amount. In this case, the total vaccine amount was 6205014 and it would
323 take about 103 years to achieve the goal. In addition, we found that the efficacy for the same amount
324 of vaccine was different during different periods. Therefore, the variable vaccination strategies
325 were further studied. We compared several cases, among which the best one was giving 175000
326 vaccine shots to girls per year in the first 5 years, followed by reducing by 15000 every 5 years. It
327 only took about 58 years to achieve the goal and the total vaccine amount was 5225000. Based on
328 these simulations, it is better to allocate more vaccines at the beginning, and then gradually reduce
329 vaccine shots. Similar results were found in another work [25]. They suggested that vaccination
330 should be applied at the maximum level and after approximately half of the time interval, the rate
331 of vaccination should be gradually reduced, reaching zero in the end. In comparison with the
332 continuous optimal control in [25], our work offered some discrete-time control strategies, which
333 would be easier to implement.

334 In this paper, we employed a simple two-sex deterministic model to evaluate the epidemiolog-
335 ical influence of HPV vaccination and used Guangxi as a case study. The model can be extended
336 to take into account more factors, such as age, sexual behavior and some other heterogeneous
337 mixing. In particular, models with age structure would be more realistic to study the spread of
338 sexually transmitted diseases such as HPV infection and its associated diseases due to the change
339 of sexual behavior with age [44, 45]. We have formulated two such models with age structure to
340 study the dynamics of HPV-associated oropharyngeal cancer and cervical cancer in Texas [19, 20].
341 The models divide the population into 23 age groups, which is challenging, if not impossible, to
342 obtain any formal analytical results. More comprehensive models would also require more data
343 for parameterization. Here we used the model with a minimum number of parameters that can be
344 calibrated by the case study, performed both analytical and numerical investigations, and provided
345 some quantitative information on the vaccine distribution strategies.

346 Vaccination of the MSM population might be crucial for disease elimination. Using a model
347 based on a network paradigm and data from Spain, Díez-Domingo et al. found that the MSM
348 group only benefits from a vaccination program that includes males [46]. From both the analysis
349 and numerical investigations in the ref. [27], we showed that in order to eliminate HPV infection,
350 the priority of vaccination should be given to MSM. Because MSM only account for a small portion
351 of the total population, in this paper we focused on the heterosexual population and studied how to
352 allocate HPV vaccine among them. Analysis of the model without MSM provides some analytical
353 results on the vaccine distribution (Theorem 8 and Corollary 1), which are difficult for the full

354 model with MSM. When the MSM population is included, numerical results would suggest similar
355 predictions as in the previous paper [27]. For example, the priority of vaccination should be given
356 to MSM for disease elimination. The heterosexual population gets great benefit but MSM only
357 get minor benefit from vaccinating heterosexual females or males. The best vaccination strategy
358 is to vaccinate MSM firstly as many as possible, then distribute the remaining to the heterosexual
359 population.

360 We used the SIS model to study the vaccination strategies in view of HPV reinfection after re-
361 recovery in both males and females [47, 48]. If we use the SIR or SIRS model, the basic reproduction
362 number R_0 remains the same and the prevalences of the male, female and total population show
363 similar dynamics. Therefore, our conclusions are not affected by the choice of these models. In
364 addition, we used the HPV prevalence as a criterion in evaluating various vaccination strategies. If
365 the objective is to reduce HPV-associated diseases such as cervical or oropharyngeal cancer, then
366 the progression from persistent HPV infection to these cancers should be incorporated into models
367 [19, 20, 31, 57–59] and the guideline of vaccination might be different from that informed by this
368 study. Lastly, the parameters and predictions are based on a case study in Guangxi Province in
369 China. This can be applied to other countries or regions. The vaccination strategies obtained in this
370 study may also be applicable to other sexually transmitted diseases.

371 Appendix A - Proof of Theorem 1

Reordering variables as $x = (I_f, I_m, S_f, S_m)^T$, the Jacobian matrix of system (2) evaluated at
the disease-free equilibrium $E^0 = (0, 0, S_f^0, S_m^0) = (0, 0, \Lambda_f/\mu_f, \Lambda_m/\mu_m)$ is

$$J(E^0) = \begin{pmatrix} J_{11} & 0 \\ J_{21} & J_{22} \end{pmatrix},$$

where

$$J_{11} = \begin{pmatrix} -(\delta_f + \mu_f) & \beta_{mf} \\ \beta_{fm} & -(\delta_m + \mu_m) \end{pmatrix},$$

and

$$J_{22} = \begin{pmatrix} -\mu_f & 0 \\ 0 & -\mu_m \end{pmatrix}.$$

372 Clearly, $-\mu_f$ and $-\mu_m$ are negative eigenvalues of $J(E^0)$. The remaining eigenvalues are determined
373 by the matrix J_{11} . If $R_0 < 1$, then we have $Tr(J_{11}) < 0$ and $det(J_{11}) = (\delta_f + \mu_f)(\delta_m + \mu_m)(1 - R_0^2) > 0$.
374 By the Routh-Hurwitz criterion [60], the DFE E^0 is locally asymptotically stable.

375 If $R_0 > 1$, then $det(J_{11}) < 0$. Hence J_{11} has an eigenvalue with positive real part. This shows
376 that E^0 is unstable.

377

378 **Appendix B - Proof of Theorem 2**

Considering the limiting system of (2), i.e. when $N_f \equiv \frac{\Lambda_f}{\mu_f}$ and $N_m \equiv \frac{\Lambda_m}{\mu_m}$, we define the following Lyapunov function

$$L = \left(S_f - S_f^0 - S_f^0 \ln \frac{S_f}{S_f^0} + I_f \right) + R_{0,mf} \left(S_m - S_m^0 - S_m^0 \ln \frac{S_m}{S_m^0} + I_m \right),$$

where $S_k^0 = \frac{\Lambda_k}{\mu_k}$, $k = f, m$. It is clear that L is radially unbounded and positive definite in the entire space D . The derivative of L along the trajectories of system (2) yields

$$\begin{aligned} \dot{L} &= \left[\left(1 - \frac{S_f^0}{S_f} \right) S_f' + I_f' \right] + R_{0,mf} \left[\left(1 - \frac{S_m^0}{S_m} \right) S_m' + I_m' \right] \\ &= \left(1 - \frac{S_f^0}{S_f} \right) (\Lambda_f - \lambda_f S_f + \delta_f I_f - \mu_f S_f) + [\lambda_f S_f - (\delta_f + \mu_f) I_f] \\ &\quad + R_{0,mf} \left\{ \left(1 - \frac{S_m^0}{S_m} \right) (\Lambda_m - \lambda_m S_m + \delta_m I_m - \mu_m S_m) + [\lambda_m S_m - (\delta_m + \mu_m) I_m] \right\}. \end{aligned}$$

Using the equilibrium conditions $\Lambda_k = \mu_k S_k^0$, $N_k = S_k^0$, $\frac{S_k^0}{S_k} \geq 1$, $k \in \{f, m\}$ and collecting terms, we obtain

$$\begin{aligned} \dot{L} &= \left[\left(1 - \frac{S_f^0}{S_f} \right) \mu_f (S_f^0 - S_f) + S_f^0 \lambda_f - \left(\frac{S_f^0}{S_f} \delta_f + \mu_f \right) I_f \right] \\ &\quad + R_{0,mf} \left[\left(1 - \frac{S_m^0}{S_m} \right) \mu_m (S_m^0 - S_m) + S_m^0 \lambda_m - \left(\frac{S_m^0}{S_m} \delta_m + \mu_m \right) I_m \right] \\ &\leq \left[-\frac{\mu_f}{S_f} (S_f^0 - S_f)^2 + \beta_{mf} I_m - (\delta_f + \mu_f) I_f \right] + R_{0,mf} \left[-\frac{\mu_m}{S_m} (S_m^0 - S_m)^2 + \beta_{fm} I_f - (\delta_m + \mu_m) I_m \right] \\ &= -\frac{\mu_f}{S_f} (S_f^0 - S_f)^2 - R_{0,mf} \frac{\mu_m}{S_m} (S_m^0 - S_m)^2 + [\beta_{mf} - R_{0,mf} (\delta_m + \mu_m)] I_m + [R_{0,mf} \beta_{fm} - (\delta_f + \mu_f)] I_f \\ &= -\frac{\mu_f}{S_f} (S_f^0 - S_f)^2 - R_{0,mf} \frac{\mu_m}{S_m} (S_m^0 - S_m)^2 + (\delta_f + \mu_f) (R_0^2 - 1) I_f. \end{aligned}$$

379 When $R_0 < 1$, we have that $\dot{L} \leq 0$ and it is equal to 0 only at the DFE. Therefore, by Krasovkii-
380 LaSalle Theorem [61], the DFE E^0 is globally asymptotically stable when $R_0 \leq 1$.

381 **Appendix C - Proof of Theorem 4**

The Jacobian matrix of system (2) evaluated at the endemic equilibrium $E^* = (I_f^*, I_m^*, S_f^*, S_m^*)$ is

$$J(E^*) = \begin{pmatrix} a_{11} & a_{12} & a_{13} & 0 \\ a_{21} & a_{22} & 0 & a_{24} \\ a_{31} & a_{32} & a_{33} & 0 \\ a_{41} & a_{42} & 0 & a_{44} \end{pmatrix},$$

where

$$\begin{aligned}
 a_{11} &= -\frac{\beta_{mf}I_m^*S_f^*}{N_f^{*2}} - (\delta_f + \mu_f) & a_{12} &= \frac{\beta_{mf}S_f^*}{N_f^*} & a_{13} &= \frac{\beta_{mf}I_m^*}{N_f^*} - \frac{\beta_{mf}I_m^*S_f^*}{N_f^{*2}}, \\
 a_{21} &= \frac{\beta_{fm}S_m^*}{N_m^*} & a_{22} &= -\frac{\beta_{fm}I_f^*S_m^*}{N_m^{*2}} - (\delta_m + \mu_m) & a_{24} &= \frac{\beta_{fm}I_f^*}{N_m^*} - \frac{\beta_{fm}I_f^*S_m^*}{N_m^{*2}}, \\
 a_{31} &= \frac{\beta_{mf}I_m^*S_f^*}{N_f^{*2}} + \delta_f & a_{32} &= -\frac{\beta_{mf}S_f^*}{N_f^*} & a_{33} &= -\frac{\beta_{mf}I_m^*}{N_f^*} + \frac{\beta_{mf}I_m^*S_f^*}{N_f^{*2}} - \mu_f, \\
 a_{41} &= -\frac{\beta_{fm}S_m^*}{N_m^*} & a_{42} &= \frac{\beta_{fm}I_f^*S_m^*}{N_m^{*2}} + \delta_m & a_{44} &= -\frac{\beta_{fm}I_f^*}{N_m^*} + \frac{\beta_{fm}I_f^*S_m^*}{N_m^{*2}} - \mu_m.
 \end{aligned}$$

Then we have

$$|J(E^*) - \lambda I| = \begin{vmatrix} a_{11} - \lambda & a_{12} & a_{13} & 0 \\ a_{21} & a_{22} - \lambda & 0 & a_{24} \\ a_{31} & a_{32} & a_{33} - \lambda & 0 \\ a_{41} & a_{42} & 0 & a_{44} - \lambda \end{vmatrix}.$$

Adding the first row to the third row, and the second row to the last row, we get

$$|J(E^*) - \lambda I| = \begin{vmatrix} a_{11} - \lambda & a_{12} & a_{13} & 0 \\ a_{21} & a_{22} - \lambda & 0 & a_{24} \\ -\mu_f - \lambda & 0 & -\mu_f - \lambda & 0 \\ 0 & -\mu_m - \lambda & 0 & -\mu_m - \lambda \end{vmatrix}.$$

The characteristic equation is

$$(\lambda + \mu_f)(\lambda + \mu_m)(\lambda^2 + b\lambda + c) = 0,$$

where

$$\begin{aligned}
 b &= \delta_f + \mu_f + \delta_m + \mu_m + \frac{\beta_{fm}I_f^*}{N_m^*} + \frac{\beta_{mf}I_m^*}{N_f^*} > 0, \\
 c &= (\delta_f + \mu_f)(\delta_m + \mu_m) + (\delta_f + \mu_f)\frac{\beta_{fm}I_f^*}{N_m^*} + (\delta_m + \mu_m)\frac{\beta_{mf}I_m^*}{N_f^*} > 0.
 \end{aligned}$$

382 Clearly, all eigenvalues of $J(E^*)$ have negative real parts. Therefore, the endemic equilibrium
 383 E^* is locally asymptotically stable when $R_0 > 1$.

384 **Appendix D - Proof of Theorem 5**

385 Considering limiting system, namely, $N_f \equiv N_f^* = \frac{\Lambda_f}{\mu_f}$ and $N_m \equiv N_m^* = \frac{\Lambda_m}{\mu_m}$, system (2) can be
386 reduced to

$$\begin{cases} I_f' = \frac{\beta_{mf}I_m(N_f^* - I_f)}{N_f^*} - (\delta_f + \mu_f)I_f, \\ I_m' = \frac{\beta_{fm}I_f(N_m^* - I_m)}{N_m^*} - (\delta_m + \mu_m)I_m. \end{cases} \quad (3)$$

This is a two-dimensional system, to which we can apply Dulac's criterion. We define

$$X = \{(I_f, I_m) \in \mathfrak{R}_+^2 : I_k \leq \Lambda_k/\mu_k, k = f, m\}.$$

Denote

$$\begin{aligned} F(I_f, I_m) &= \frac{\beta_{mf}I_m(N_f^* - I_f)}{N_f^*} - (\delta_f + \mu_f)I_f, \\ G(I_f, I_m) &= \frac{\beta_{fm}I_f(N_m^* - I_m)}{N_m^*} - (\delta_m + \mu_m)I_m. \end{aligned}$$

Using 1 as the Dulac multiplier, we get

$$\frac{\partial F(I_f, I_m)}{\partial I_f} + \frac{\partial G(I_f, I_m)}{\partial I_m} = -\frac{\beta_{mf}I_m}{N_f^*} - (\delta_f + \mu_f) - \frac{\beta_{fm}I_f}{N_m^*} - (\delta_m + \mu_m) < 0.$$

387 Therefore, there are no periodic orbits in region X [61]. Since the unique endemic equilibrium E^*
388 is locally asymptotically stable when $R_0 > 1$, it is globally asymptotically stable when $R_0 > 1$.

389 **Appendix E - Proof of Theorem 7**

390 To get the endemic equilibrium, we set the right-hand side of system (1) to zero. At the equi-
391 librium, we use $N_k^* - V_k - I_k$ to replace S_k , where $N_k^* = \Lambda_k/\mu_k, k \in \{f, m\}$. It follows that

$$\begin{cases} \phi_f \Lambda_f - (1 - \tau)\lambda_f V_f - \mu_f V_f = 0, \\ \lambda_f(N_f^* - \tau V_f - I_f) - (\delta_f + \mu_f)I_f = 0, \\ \phi_m \Lambda_m - (1 - \tau)\lambda_m V_m - \mu_m V_m = 0, \\ \lambda_m(N_m^* - \tau V_m - I_m) - (\delta_m + \mu_m)I_m = 0, \end{cases} \quad (4)$$

where

$$\lambda_k = \frac{\beta_{k'k}I_{k'}}{N_k^*}, \quad k, k' \in \{f, m\}, \quad k \neq k'.$$

From the third equation of (4), we get

$$V_m = \frac{\phi_m \Lambda_m}{(1 - \tau)\lambda_m + \mu_m} = \frac{\phi_m \Lambda_m}{(1 - \tau)\frac{\beta_{fm} I_f}{N_m^*} + \mu_m}, \text{ denoted by } g_1(I_f).$$

From the last equation of (4), we have $I_m = g_2(I_f)I_f$, where

$$g_2(I_f) = \frac{[N_m^* - \tau g_1(I_f)]\frac{\beta_{fm}}{N_m^*}}{\frac{\beta_{fm}}{N_m^*} I_f + \delta_m + \mu_m}.$$

Substituting into the first equation of (4), we get

$$V_f = \frac{\phi_f \Lambda_f}{(1 - \tau)\lambda_f + \mu_f} = \frac{\phi_f \Lambda_f}{(1 - \tau)\frac{\beta_{mf} g_2(I_f) I_f}{N_f^*} + \mu_f}, \text{ denoted by } g_3(I_f).$$

Substituting into the second equation of (4), we have

$$\frac{\beta_{mf}}{N_f^*} g_2(I_f) I_f [N_f^* - \tau g_3(I_f) - I_f] - (\delta_f + \mu_f) I_f = 0.$$

Define

$$G(I_f) = \frac{\beta_{mf}}{N_f^*} g_2(I_f) [N_f^* - \tau g_3(I_f) - I_f] - (\delta_f + \mu_f).$$

We notice that

$$g_1(0) = \phi_m N_m^*, \quad g_2(0) = \frac{(1 - \tau \phi_m) \beta_{fm}}{\delta_m + \mu_m}, \quad g_3(0) = \phi_f N_f^*.$$

Hence

$$\begin{aligned} G(0) &= \frac{\beta_{mf}}{N_f^*} g_2(0) [N_f^* - \tau g_3(0)] - (\delta_f + \mu_f) \\ &= \frac{\beta_{mf}}{N_f^*} \frac{(1 - \tau \phi_m) \beta_{fm}}{\delta_m + \mu_m} [N_f^* - \tau \phi_f N_f^*] - (\delta_f + \mu_f) \\ &= \frac{\beta_{mf} \beta_{fm} (1 - \tau \phi_m) (1 - \tau \phi_f)}{\delta_m + \mu_m} - (\delta_f + \mu_f) \\ &= (\delta_f + \mu_f) [R_0^2(\phi_f, \phi_m) - 1]. \end{aligned}$$

Thus, $G(0) > 0$ when $R_0(\phi_f, \phi_m) > 1$. On the other hand,

$$\lim_{I_f \rightarrow N_f^*} g_1(I_f) = \lim_{I_f \rightarrow N_f^*} \frac{\phi_m \Lambda_m}{(1 - \tau)\frac{\beta_{fm} I_f}{N_m^*} + \mu_m} < \frac{\phi_m \Lambda_m}{\mu_m} = \phi_m N_m^* \leq N_m^*.$$

Hence, $\lim_{I_f \rightarrow N_f^*} [N_m^* - \tau g_1(I_f)] > 0$. Consequently

$$\lim_{I_f \rightarrow N_f^*} g_2(I_f) = \lim_{I_f \rightarrow N_f^*} \frac{[N_m^* - \tau g_1(I_f)] \frac{\beta_{fm}}{N_m^*}}{\frac{\beta_{fm}}{N_m^*} I_f + \delta_m + \mu_m} > 0.$$

It follows that

$$\lim_{I_f \rightarrow N_f^*} g_3(I_f) = \lim_{I_f \rightarrow N_f^*} \frac{\phi_f \Lambda_f}{(1 - \tau) \frac{\beta_{mf} g_2(I_f) I_f}{N_f^*} + \mu_f} \geq 0.$$

Therefore,

$$\lim_{I_f \rightarrow N_f^*} [N_f^* - \tau g_3(I_f) - I_f] \leq \lim_{I_f \rightarrow N_f^*} (N_f^* - I_f) = 0.$$

Since $\lim_{I_f \rightarrow N_f^*} g_2(I_f) > 0$,

$$\lim_{I_f \rightarrow N_f^*} G(I_f) = \lim_{I_f \rightarrow N_f^*} \left\{ \frac{\beta_{mf}}{N_f^*} g_2(I_f) [N_f^* - \tau g_3(I_f) - I_f] - (\delta_f + \mu_f) \right\} \leq -(\delta_f + \mu_f) < 0.$$

392 Therefore, there exists $I_f^* \in (0, N_f^*)$ such that $G(I_f^*) = 0$. It follows that $V_m^* = g_1(I_f^*) \in (0, \phi_m N_m^*)$,
 393 which indicates $g_2(I_f^*) > 0$. Hence $I_m^* = g_2(I_f^*) I_f^* > 0$. Since $\lambda_m^* = \beta_{fm} I_f^* / N_m^* > 0$, we have
 394 $S_m^* = [(1 - \phi_m) \Lambda_m + \delta_m I_m^*] / (\lambda_m^* + \mu_m) > 0$. Since $S_m^* + V_m^* + I_m^* = N_m^*$, we have $S_m^*, V_m^*, I_m^* \in (0, N_m^*)$.
 395 Similarly, we have $S_f^*, V_f^*, I_f^* \in (0, N_f^*)$. This completes the proof.

396 Appendix F - Proof of Theorem 8

From $\phi_f \Lambda_f + \phi_m \Lambda_m = v$, we derive $\phi_m = \frac{v - \phi_f \Lambda_f}{\Lambda_m}$. It follows that

$$\begin{aligned} R_0^2(\phi_f, \phi_m) &= \frac{\beta_{mf} \beta_{fm}}{(\delta_m + \mu_m)(\delta_f + \mu_f)} (1 - \tau \phi_f)(1 - \tau \phi_m) \\ &= \frac{\beta_{mf} \beta_{fm}}{(\delta_m + \mu_m)(\delta_f + \mu_f)} (1 - \tau \phi_f) \left(1 - \tau \frac{v - \phi_f \Lambda_f}{\Lambda_m} \right), \end{aligned}$$

where

$$\max \left\{ 0, \frac{v - \Lambda_m}{\Lambda_f} \right\} \leq \phi_f \leq \min \left\{ 1, \frac{v}{\Lambda_f} \right\}.$$

397 We have 4 cases.

398 **Case 1.** $v \leq \Lambda_f$ and $v \leq \Lambda_m$.

It is easy to check that

$$\max \left\{ 0, \frac{v - \Lambda_m}{\Lambda_f} \right\} = 0, \quad \min \left\{ 1, \frac{v}{\Lambda_f} \right\} = \frac{v}{\Lambda_f}.$$

Hence

$$0 \leq \phi_f \leq \frac{v}{\Lambda_f}.$$

The value $\min R_0^2(\phi_f, \phi_m)$ can only be attained at point $\phi_f = 0$ or $\phi_f = \frac{v}{\Lambda_f}$. Since

$$R_0^2|_{\phi_f=0} = \frac{\beta_{mf}\beta_{fm}}{(\delta_m + \mu_m)(\delta_f + \mu_f)} \left(1 - \tau \frac{v}{\Lambda_m}\right),$$

$$R_0^2|_{\phi_f=\frac{v}{\Lambda_f}} = \frac{\beta_{mf}\beta_{fm}}{(\delta_m + \mu_m)(\delta_f + \mu_f)} \left(1 - \tau \frac{v}{\Lambda_f}\right),$$

399 and $\min R_0$ and $\min R_0^2$ are obtained at the same point, we have the following results:

400 (a) When $v \leq \Lambda_m < \Lambda_f$, $\min R_0(\phi_f, \phi_m)$ is attained at point $\phi_f = 0$, $\phi_m = \frac{v}{\Lambda_m}$;

401 (b) When $v \leq \Lambda_f < \Lambda_m$, $\min R_0(\phi_f, \phi_m)$ is attained at point $\phi_f = \frac{v}{\Lambda_f}$, $\phi_m = 0$;

402 (c) When $v \leq \Lambda_f = \Lambda_m$, $\min R_0(\phi_f, \phi_m)$ is attained at point $\phi_f = 0$, $\phi_m = \frac{v}{\Lambda_m}$ or $\phi_f = \frac{v}{\Lambda_f}$, $\phi_m = 0$.

403

404 **Case 2.** $\Lambda_f < v \leq \Lambda_m$.

In this case, we have

$$\max \left\{ 0, \frac{v - \Lambda_m}{\Lambda_f} \right\} = 0, \quad \min \left\{ 1, \frac{v}{\Lambda_f} \right\} = 1.$$

Thus, $0 \leq \phi_f \leq 1$. By the same reason as above, we compare

$$R_0^2|_{\phi_f=0} = \frac{\beta_{mf}\beta_{fm}}{(\delta_m + \mu_m)(\delta_f + \mu_f)} \left(1 - \tau \frac{v}{\Lambda_m}\right)$$

and

$$R_0^2|_{\phi_f=1} = \frac{\beta_{mf}\beta_{fm}}{(\delta_m + \mu_m)(\delta_f + \mu_f)} (1 - \tau) \left(1 - \tau \frac{v - \Lambda_f}{\Lambda_m}\right).$$

405 Since $\Lambda_f < v \leq \Lambda_m$ and $v \leq \Lambda_f + \Lambda_m$, we have $1 - \tau \leq 1 - \tau \frac{v}{\Lambda_m}$ and $0 \leq 1 - \tau \leq 1 - \tau \frac{v - \Lambda_f}{\Lambda_m} < 1$,

406 which implies $R_0^2|_{\phi_f=0} > R_0^2|_{\phi_f=1}$. Therefore, we have the following result:

407 (d) When $\Lambda_f < v \leq \Lambda_m$, $\min R_0(\phi_f, \phi_m)$ is attained at point $\phi_f = 1$, $\phi_m = \frac{v - \Lambda_f}{\Lambda_m}$.

408

409 **Case 3.** $\Lambda_m < v \leq \Lambda_f$.

410 By similar argument as in Case 2, we can derive the following result:

411 (e) When $\Lambda_m < v \leq \Lambda_f$, $\min R_0(\phi_f, \phi_m)$ is attained at point $\phi_f = \frac{v - \Lambda_m}{\Lambda_f}$, $\phi_m = 1$.

412

413 **Case 4.** $v > \Lambda_f$ and $v > \Lambda_m$.

By similar argument as above, we compare

$$R_0^2|_{\phi_f=\frac{v-\Lambda_m}{\Lambda_f}} = \frac{\beta_{mf}\beta_{fm}}{(\delta_m + \mu_m)(\delta_f + \mu_f)} \left(1 - \tau \frac{v - \Lambda_m}{\Lambda_f}\right) (1 - \tau)$$

and

$$R_0^2|_{\phi_f=1} = \frac{\beta_{mf}\beta_{fm}}{(\delta_m + \mu_m)(\delta_f + \mu_f)}(1 - \tau)\left(1 - \tau\frac{v - \Lambda_f}{\Lambda_m}\right).$$

414 When $\Lambda_f < \Lambda_m$, from $v \leq \Lambda_f + \Lambda_m$ we have $(\Lambda_m - \Lambda_f)v \leq \Lambda_m^2 - \Lambda_f^2$. Hence $\frac{v - \Lambda_m}{\Lambda_f} \leq \frac{v - \Lambda_f}{\Lambda_m}$. This
 415 implies $R_0^2|_{\phi_f=\frac{v-\Lambda_m}{\Lambda_f}} \geq R_0^2|_{\phi_f=1}$. Similarly, when $\Lambda_f > \Lambda_m$, we can derive $R_0^2|_{\phi_f=\frac{v-\Lambda_m}{\Lambda_f}} \leq R_0^2|_{\phi_f=1}$.

416 Therefore, we have the following results:

417 (f) When $\Lambda_f < \Lambda_m < v$, $\min R_0(\phi_f, \phi_m)$ is attained at point $\phi_f = 1$, $\phi_m = \frac{v - \Lambda_f}{\Lambda_m}$;

418 (g) When $\Lambda_m < \Lambda_f < v$, $\min R_0(\phi_f, \phi_m)$ is attained at point $\phi_f = \frac{v - \Lambda_m}{\Lambda_f}$, $\phi_m = 1$;

419 (h) When $\Lambda_f = \Lambda_m < v$, $\min R_0(\phi_f, \phi_m)$ is attained at point $\phi_f = 1$, $\phi_m = \frac{v - \Lambda_f}{\Lambda_m}$ or $\phi_f = \frac{v - \Lambda_m}{\Lambda_f}$,
 420 $\phi_m = 1$.

421 Summing up all the results from (a)-(h), we get the following results. If $\Lambda_k \leq \Lambda_{k'}$, $\min R_0(\phi_f, \phi_m)$

422 is attained at: (i) $\phi_k = \frac{v}{\Lambda_k}$, $\phi_{k'} = 0$ when $v \leq \Lambda_k$; (ii) $\phi_k = 1$, $\phi_{k'} = \frac{v - \Lambda_k}{\Lambda_{k'}}$ when $v > \Lambda_k$, where

423 $k, k' \in \{f, m\}$ and $k \neq k'$.

424 Considering the special case $\Lambda_f = \Lambda_m = \Lambda$, we only have Case 1 and Case 4. If we consider

425 $R_0^2(\phi_f, \phi_m)$ as a function of ϕ_f , then it becomes a quadratic function, which has the axis of symmetry

426 $\phi_f = \frac{v}{2\Lambda}$. In either case, from $v \leq 2\Lambda$ we have $\max\{0, \frac{v - \Lambda}{\Lambda}\} \leq \phi_f^* = \frac{v}{2\Lambda} \leq \min\{1, \frac{v}{\Lambda}\}$. According

427 to the properties of quadratic functions, $\max R_0(\phi_f, \phi_m)$ can be achieved at ϕ_f^* , and the closer ϕ_f

428 approaches ϕ_f^* , the bigger R_0 is. Moreover, $\phi_f^* = \frac{v}{2\Lambda}$ corresponds to $\phi_f^* = \phi_m^* = \frac{v}{2\Lambda}$. When ϕ_f

429 approaches ϕ_f^* , ϕ_f and ϕ_m are getting closer to each other. In other words, when $\Lambda_f = \Lambda_m = \Lambda$,

430 $\max R_0(\phi_f, \phi_m)$ is attained at $\phi_f = \phi_m = \frac{v}{2\Lambda}$, and the smaller $|\phi_f - \phi_m|$, the bigger $R_0(\phi_f, \phi_m)$.

431 Appendix G - Proof of Corollary 1

Considering $\min R_0^2$ as a function of the vaccine amount v and denote it by $h(v)$, we can summarize the results from Appendix F as follows:

(i) When $\Lambda_f \leq \Lambda_m$

$$h(v) = \begin{cases} R_0^2\left(\frac{v}{\Lambda_f}, 0\right) = \frac{\beta_{mf}\beta_{fm}}{(\delta_m + \mu_m)(\delta_f + \mu_f)}\left(1 - \tau\frac{v}{\Lambda_f}\right), & v \leq \Lambda_f, \\ R_0^2\left(1, \frac{v - \Lambda_f}{\Lambda_m}\right) = \frac{\beta_{mf}\beta_{fm}}{(\delta_m + \mu_m)(\delta_f + \mu_f)}(1 - \tau)\left(1 - \tau\frac{v - \Lambda_f}{\Lambda_m}\right), & v > \Lambda_f. \end{cases}$$

(ii) When $\Lambda_f > \Lambda_m$

$$h(v) = \begin{cases} R_0^2\left(0, \frac{v}{\Lambda_m}\right) = \frac{\beta_{mf}\beta_{fm}}{(\delta_m + \mu_m)(\delta_f + \mu_f)}\left(1 - \tau\frac{v}{\Lambda_m}\right), & v \leq \Lambda_m, \\ R_0^2\left(\frac{v - \Lambda_m}{\Lambda_f}, 1\right) = \frac{\beta_{mf}\beta_{fm}}{(\delta_m + \mu_m)(\delta_f + \mu_f)}\left(1 - \tau\frac{v - \Lambda_m}{\Lambda_f}\right)(1 - \tau), & v > \Lambda_m. \end{cases}$$

For Case (i), the derivative is

$$h'(v) = \begin{cases} -\frac{\beta_{mf}\beta_{fm}}{(\delta_m+\mu_m)(\delta_f+\mu_f)}\frac{\tau}{\Lambda_f}, & v \leq \Lambda_f, \\ -\frac{\beta_{mf}\beta_{fm}}{(\delta_m+\mu_m)(\delta_f+\mu_f)}(1-\tau)\frac{\tau}{\Lambda_m}, & v > \Lambda_f. \end{cases}$$

432 We have $h'(v) < 0$. Since $\Lambda_f \leq \Lambda_m$, we have $\frac{1}{\Lambda_f} > \frac{1-\tau}{\Lambda_m}$. Therefore, $|h'(v)|$ is smaller for $v \leq \Lambda_f$
433 than that for $v > \Lambda_f$. This shows that $h(v)$ is a decreasing function and the decline speed when
434 $v \leq \Lambda_f$ is greater than that when $v > \Lambda_f$. This means that the vaccination becomes less effective
435 once vaccine shots exceed the number of female recruits. A similar conclusion can be drawn for
436 Case (ii).

437 **Appendix H - Estimation of the numbers of 14-year-old boys and girls in Guangxi in 2021-** 438 **2033**

439 Under-five mortality rate (U5MR) is the probability of dying by age 5 per 1000 live births.
440 The probability of dying among children aged 5-14 is about 18% of U5MR in the same year
441 [62, 63]. Therefore, we estimate the number of children who are alive by age 14 to be newborn*(1-
442 U5MR-U5MR*18%). The national census is only conducted at the year ending with 0, and the 1%
443 national sample census is conducted at the year ending with 5. According to [64, 65], the sex ratio
444 (male/female) is 115.6 (assume females are 100) for newborns in 1995 in China, and it is 112.06
445 for 15-year-old children in 2010. Thus, we estimate the sex ratio at age 14 to be the sex ratio at
446 newborn (same cohort)- $\frac{14}{15} \times (115.6 - 112.06)$. Using the number of 14 year-old children and the
447 sex ratio for age 14, we can estimate the numbers of 14-year-old girls and boys in 2021-2033. The
448 results are given in Table 8.

449 **Acknowledgments**

450 This work was supported by the NSF grants DMS-1951595 (MM), DMS-1620957 (MH) and
451 DMS-1950254 (LR).

452 **References**

- 453 [1] WHO, HPV: key facts, [https://www.who.int/news-room/fact-sheets/detail/human-](https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer)
454 [papillomavirus-\(hpv\)-and-cervical-cancer](https://www.who.int/news-room/fact-sheets/detail/human-papillomavirus-(hpv)-and-cervical-cancer) (2021).
- 455 [2] J. Lei, A. Ploner, K. M. Elfström, J. Wang, A. Roth, F. Fang, K. Sundström, J. Dillner,
456 P. Sparén, HPV vaccination and the risk of invasive cervical cancer, *New England Journal*
457 *of Medicine* 383 (14) (2020) 1340–1348.

- 458 [3] E. Petrosky, J. A. Bocchini Jr, S. Hariri, H. Chesson, C. R. Curtis, M. Saraiya, E. R. Unger,
459 L. E. Markowitz, Use of 9-valent human papillomavirus (HPV) vaccine: updated HPV vac-
460 cination recommendations of the advisory committee on immunization practices, *Morbidity*
461 *and Mortality Weekly Report* 64 (11) (2015) 300.
- 462 [4] WHO, HPV: News, [https://www.who.int/news-room/detail/31-10-2019-major-milestone-](https://www.who.int/news-room/detail/31-10-2019-major-milestone-reached-as-100-countries-have-introduced-hpv-vaccine-into-national-schedule)
463 [reached-as-100-countries-have-introduced-hpv-vaccine-into-national-schedule](https://www.who.int/news-room/detail/31-10-2019-major-milestone-reached-as-100-countries-have-introduced-hpv-vaccine-into-national-schedule) (2019).
- 464 [5] Australian Government Department of Health, Human papillomavirus (HPV) im-
465 munisation service, [https://www.health.gov.au/health-topics/immunisation/immunisation-](https://www.health.gov.au/health-topics/immunisation/immunisation-services/human-papillomavirus-hpv-immunisation-service)
466 [services/human-papillomavirus-hpv-immunisation-service](https://www.health.gov.au/health-topics/immunisation/immunisation-services/human-papillomavirus-hpv-immunisation-service) (2021).
- 467 [6] Centers for Disease Control and Prevention (CDC), Human Papillomavirus (HPV) Fact Sheet,
468 <https://www.cdc.gov/std/hpv/stdfact-hpv.htm> (2021).
- 469 [7] A. Green, HPV vaccine to be offered to boys in England, *The Lancet* 392 (10145) (2018) 374.
- 470 [8] S. Arie, [HPV: WHO calls for countries to suspend vaccination of boys](#), *BMJ: British Medical*
471 *Journal (Online)* 367.
472 URL <https://www.bmj.com/content/367/bmj.16765>
- 473 [9] M. Stanley, Perspective: vaccinate boys too, *Nature* 488 (7413) (2012) S10–S10.
- 474 [10] M. Brisson, É. Bénard, M. Drolet, J. A. Bogaards, I. Baussano, S. Vänskä, M. Jit, M.-C. Boily,
475 M. A. Smith, J. Berkhof, et al., Population-level impact, herd immunity, and elimination after
476 human papillomavirus vaccination: a systematic review and meta-analysis of predictions from
477 transmission-dynamic models, *The Lancet Public Health* 1 (1) (2016) e8–e17.
- 478 [11] E. H. Elbasha, E. J. Dasbach, R. P. Insinga, Model for assessing human papillomavirus vac-
479 cination strategies, *Emerging Infectious Diseases* 13 (1) (2007) 28.
- 480 [12] E. H. Elbasha, E. J. Dasbach, R. P. Insinga, A multi-type HPV transmission model, *Bulletin*
481 *of Mathematical Biology* 70 (8) (2008) 2126–2176.
- 482 [13] E. H. Elbasha, E. J. Dasbach, Impact of vaccinating boys and men against HPV in the United
483 States, *Vaccine* 28 (42) (2010) 6858–6867.
- 484 [14] R. P. Insinga, E. J. Dasbach, E. H. Elbasha, A. Puig, L. M. Reynales-Shigematsu, Cost-
485 effectiveness of quadrivalent human papillomavirus (HPV) vaccination in Mexico: a trans-
486 mission dynamic model-based evaluation, *Vaccine* 26 (1) (2007) 128–139.
- 487 [15] F. S. Mennini, P. Bonanni, F. Bianic, C. de Waure, G. Baio, G. Plazzotta, M. Uhart, A. Ri-
488 naldi, N. Llargeron, Cost-effectiveness analysis of the nine-valent HPV vaccine in Italy, *Cost*
489 *Effectiveness and Resource Allocation* 15 (1) (2017) 1–14.

- 490 [16] P. Cody, K. Tobe, M. Abe, E. H. Elbasha, Public health impact and cost effectiveness of
491 routine and catch-up vaccination of girls and women with a nine-valent HPV vaccine in Japan:
492 a model-based study, *BMC Infectious Diseases* 21 (1) (2021) 1–13.
- 493 [17] L. Majed, X. Bresse, N. El Mouaddin, A. Schmidt, V. J. Daniels, A. Pavelyev, L. Levy-
494 Bachelot, E. Elbasha, Public health impact and cost-effectiveness of a nine-valent gender-
495 neutral HPV vaccination program in France, *Vaccine* 39 (2) (2021) 438–446.
- 496 [18] V. Daniels, V. S. Prabhu, C. Palmer, S. Samant, S. Kothari, C. Roberts, E. Elbasha, Pub-
497 lic health impact and cost-effectiveness of catch-up 9-valent HPV vaccination of individuals
498 through age 45 years in the United States, *Human Vaccines & Immunotherapeutics* (2021)
499 1–9.
- 500 [19] H.-L. Peng, S. Tam, L. Xu, K. R. Dahlstrom, C.-F. Wu, S. Fu, C. Zhong, W. Chan, E. M.
501 Sturgis, L. Ramondetta, et al., Age-structured population modeling of HPV-related cervical
502 cancer in Texas and US, *Scientific Reports* 8 (1) (2018) 1–12.
- 503 [20] C. Zhong, L. Xu, H.-L. Peng, S. Tam, K. R. Dahlstrom, C.-F. Wu, S. Fu, W. Chan, E. M.
504 Sturgis, L. M. Ramondetta, et al., An economic and disease transmission model of human
505 papillomavirus and oropharyngeal cancer in Texas, *Scientific Reports* 11 (1) (2021) 1–16.
- 506 [21] K. Haeussler, A. Marcellusi, F. S. Mennini, G. Favato, M. Picardo, G. Garganese, M. Bononi,
507 S. Costa, G. Scambia, P. Zweifel, et al., Cost-effectiveness analysis of universal human papil-
508 lomavirus vaccination using a dynamic Bayesian methodology: the BEST II study, *Value in*
509 *Health* 18 (8) (2015) 956–968.
- 510 [22] J. Kim, B. Andres-Beck, S. Goldie, The value of including boys in an HPV vaccination pro-
511 gramme: a cost-effectiveness analysis in a low-resource setting, *British Journal of Cancer*
512 97 (9) (2007) 1322–1328.
- 513 [23] H. W. Chesson, D. U. Ekwueme, M. Saraiya, E. F. Dunne, L. E. Markowitz, The cost-
514 effectiveness of male HPV vaccination in the United States, *Vaccine* 29 (46) (2011) 8443–
515 8450.
- 516 [24] J. J. Kim, S. J. Goldie, Health and economic implications of HPV vaccination in the United
517 States, *New England Journal of Medicine* 359 (8) (2008) 821–832.
- 518 [25] F. Saldaña, J. A. Camacho-Gutiérrez, I. Barradas, A. Korobeinikov, When optimal is not the
519 best: cost effectiveness analysis for HPV epidemic models, arXiv preprint arXiv:2011.06594.
- 520 [26] O. Damm, J. Horn, R. T. Mikolajczyk, M. E. Kretzschmar, A. M. Kaufmann, Y. Deléré,
521 B. Ulsch, O. Wichmann, A. Krämer, W. Greiner, Cost-effectiveness of human papillomavirus
522 vaccination in Germany, *Cost Effectiveness and Resource Allocation* 15 (1) (2017) 1–19.

- 523 [27] S. Gao, M. Martcheva, H. Miao, L. Rong, A dynamic model to assess human papillomavirus
524 vaccination strategies in a heterosexual population combined with men who have sex with
525 men, *Bulletin of Mathematical Biology* 83 (1) (2021) 1–36.
- 526 [28] J. A. Bogaards, M. Kretzschmar, M. Xiridou, C. J. Meijer, J. Berkhof, J. Wallinga, Sex-
527 specific immunization for sexually transmitted infections such as human papillomavirus: in-
528 sights from mathematical models, *PLoS Med* 8 (12) (2011) e1001147.
- 529 [29] R. V. Barnabas, G. P. Garnett, 5. The potential public health impact of vaccines against human
530 papillomavirus, *HPV Handbook* (2004) 61.
- 531 [30] M. Brisson, N. van de Velde, E. L. Franco, M. Drolet, M.-C. Boily, Incremental impact of
532 adding boys to current human papillomavirus vaccination programs: role of herd immunity,
533 *Journal of Infectious Diseases* 204 (3) (2011) 372–376.
- 534 [31] R. V. Barnabas, P. Laukkanen, P. Koskela, O. Kontula, M. Lehtinen, G. P. Garnett, Epidemi-
535 ology of HPV 16 and cervical cancer in Finland and the potential impact of vaccination:
536 mathematical modelling analyses, *PLoS Med* 3 (5) (2006) e138.
- 537 [32] F. Azevedo, L. Esteva, C. P. Ferreira, Assessing the impact of prophylactic vaccines on HPV
538 prevalence, *TEMA (São Carlos)* 20 (2) (2019) 305–321.
- 539 [33] J. Horn, O. Damm, M. Kretzschmar, Y. Deleré, O. Wichmann, A. Kaufmann, E. Garbe,
540 A. Krämer, W. Greiner, R. Mikolajczyk, Estimating the long-term effects of HPV vaccina-
541 tion in Germany, *Vaccine* 31 (19) (2013) 2372–2380.
- 542 [34] V. Brown, K. A. White, The HPV vaccination strategy: could male vaccination have a signifi-
543 cant impact?, *Computational and Mathematical Methods in Medicine* 11 (3) (2010) 223–237.
- 544 [35] E. H. Elbasha, Impact of prophylactic vaccination against human papillomavirus infection,
545 *Contemporary Mathematics* 410 (2006) 113–128.
- 546 [36] E. H. Elbasha, Global stability of equilibria in a two-sex HPV vaccination model, *Bulletin of*
547 *Mathematical Biology* 70 (3) (2008) 894.
- 548 [37] L. Ribassin-Majed, R. Lounes, S. Cléménçon, Deterministic modelling for transmission of
549 Human Papillomavirus 6/11: impact of vaccination, *Mathematical Medicine and Biology: a*
550 *Journal of the IMA* 31 (2) (2014) 125–149.
- 551 [38] N. Ziyadi, A male-female mathematical model of human papillomavirus (HPV) in African
552 American population, *Mathematical Biosciences & Engineering* 14 (1) (2017) 339.
- 553 [39] O. Sharomi, T. Malik, A model to assess the effect of vaccine compliance on Human Papillo-
554 mavirus infection and cervical cancer, *Applied Mathematical Modelling* 47 (2017) 528–550.

- 555 [40] K. Zhang, X. W. Wang, H. Liu, Y. P. Ji, Q. Pan, Y. M. Wei, X. Ma, Mathematical analysis of
556 a human papillomavirus transmission model with vaccination and screening, *Mathematical*
557 *Biosciences and Engineering* 17 (5) (2020) 5449–5476.
- 558 [41] A. Omame, R. Umama, D. Okuonghae, S. Inyama, Mathematical analysis of a two-sex Hu-
559 man Papillomavirus (HPV) model, *International Journal of Biomathematics* 11 (07) (2018)
560 1850092.
- 561 [42] T. Malik, A. Gumel, E. H. Elbasha, Qualitative analysis of an age-and sex-structured vaccina-
562 tion model for human papillomavirus, *Discrete & Continuous Dynamical Systems-B* 18 (8)
563 (2013) 2151.
- 564 [43] T. Malik, J. Reimer, A. Gumel, E. H. Elbasha, S. Mahmud, The impact of an imperfect vaccine
565 and pap cytology screening on the transmission of human papillomavirus and occurrence of
566 associated cervical dysplasia and cancer, *Mathematical Biosciences & Engineering* 10 (4)
567 (2013) 1173.
- 568 [44] C. Muñoz-Quiles, J. Díez-Domingo, L. Acedo, V. Sánchez-Alonso, R. J. Villanueva, On the
569 elimination of infections related to oncogenic human papillomavirus: An approach using a
570 computational network model, *Viruses* 13 (5) (2021) 906.
- 571 [45] L. Acedo, J.-C. Cortés, J. Díez-Domingo, V. Sánchez-Alonso, J. Tuells, R.-J. Villanueva, Un-
572 certainty and sensitivity of the sexual behavior changes to the current human papillomavirus
573 vaccination campaign in Spain, *Mathematical Methods in the Applied Sciences* 44 (9) (2021)
574 7845–7857.
- 575 [46] J. Díez-Domingo, V. Sánchez-Alonso, R.-J. Villanueva, L. Acedo, J. Tuells, Impact of a
576 gender-neutral HPV vaccination program in men who have sex with men (MSM), *Internation-
577 al Journal of Environmental Research and Public Health* 18 (3) (2021) 963.
- 578 [47] S. L. Ranjeva, E. B. Baskerville, V. Dukic, L. L. Villa, E. Lazcano-Ponce, A. R. Giuliano,
579 G. Dwyer, S. Cobey, Recurring infection with ecologically distinct HPV types can explain
580 high prevalence and diversity, *Proceedings of the National Academy of Sciences* 114 (51)
581 (2017) 13573–13578.
- 582 [48] H. Trottier, S. Ferreira, P. Thomann, M. C. Costa, J. S. Sobrinho, J. C. M. Prado, T. E. Rohan,
583 L. L. Villa, E. L. Franco, Human papillomavirus infection and reinfection in adult women:
584 the role of sexual activity and natural immunity, *Cancer Research* 70 (21) (2010) 8569–8577.
- 585 [49] P. Van den Driessche, J. Watmough, Reproduction numbers and sub-threshold endemic equi-
586 libria for compartmental models of disease transmission, *Mathematical Biosciences* 180 (1-2)
587 (2002) 29–48.

- 588 [50] F. Wei, M. Guo, S. Huang, M. Li, X. Cui, Y. Su, X. Wu, X. Ma, Y. Zheng, Y. Huang, et al.,
589 Sex differences in the incidence and clearance of anogenital human papillomavirus infection
590 in Liuzhou, China: an observational cohort study, *Clinical Infectious Diseases* 70 (1) (2020)
591 82–89.
- 592 [51] F. Wei, K. Yin, X. Wu, J. Lan, S. Huang, W. Sheng, J. Zhao, Y. Su, Y. Wang, Y. Li, et al.,
593 Human papillomavirus prevalence and associated factors in women and men in south China:
594 a population-based study, *Emerging Microbes & Infections* 5 (1) (2016) 1–8.
- 595 [52] Liuzhou statistical yearbook, [http://lztj.liuzhou.gov.cn/xxgk/jcxxgk/sjfb/tjnj/201811/
596 P020181113530838124483.pdf](http://lztj.liuzhou.gov.cn/xxgk/jcxxgk/sjfb/tjnj/201811/P020181113530838124483.pdf) (2015).
- 597 [53] P. J. Woestenberg, A. J. King, B. H. Van Benthem, R. Donken, S. Leussink, F. R. Van Der Klis,
598 H. E. De Melker, M. A. Van Der Sande, C. J. Hoebe, J. A. Bogaards, et al., Bivalent vac-
599 cine effectiveness against type-specific HPV positivity: evidence for cross-protection against
600 oncogenic types among Dutch STI clinic visitors, *The Journal of Infectious Diseases* 217 (2)
601 (2018) 213–222.
- 602 [54] S. Marino, I. B. Hogue, C. J. Ray, D. E. Kirschner, A methodology for performing global
603 uncertainty and sensitivity analysis in systems biology, *Journal of Theoretical Biology* 254 (1)
604 (2008) 178–196.
- 605 [55] R. Taylor, Interpretation of the correlation coefficient: a basic review, *Journal of Diagnostic
606 Medical Sonography* 6 (1) (1990) 35–39.
- 607 [56] M. Riesen, V. Garcia, N. Low, C. L. Althaus, Modeling the consequences of regional hetero-
608 geneity in human papillomavirus (HPV) vaccination uptake on transmission in Switzerland,
609 *Vaccine* 35 (52) (2017) 7312–7321.
- 610 [57] S. L. Lee, A. M. Tameru, A mathematical model of human papillomavirus (HPV) in the
611 United States and its impact on cervical cancer, *Journal of Cancer* 3 (2012) 262–268.
- 612 [58] A. F. Brouwer, M. C. Eisenberg, R. Meza, Age effects and temporal trends in HPV-related
613 and HPV-unrelated oral cancer in the United States: a multistage carcinogenesis modeling
614 analysis, *PloS One* 11 (3) (2016) e0151098.
- 615 [59] I. Baussano, G. Ronco, N. Segnan, K. French, P. Vineis, G. P. Garnett, HPV-16 infection and
616 cervical cancer: modeling the influence of duration of infection and precancerous lesions,
617 *Epidemics* 2 (1) (2010) 21–28.
- 618 [60] F. R. Gantmakher, *The theory of matrices*, Vol. 131, American Mathematical Soc., 1959.
- 619 [61] M. Martcheva, *An introduction to mathematical epidemiology*, Vol. 61, Springer, 2015.

- 620 [62] Under-five mortality rate (probability of dying by age 5 per 1000 live births),
621 [https://www.who.int/data/gho/data/indicators/indicator-details/GHO/under-five-mortality-](https://www.who.int/data/gho/data/indicators/indicator-details/GHO/under-five-mortality-rate-(probability-of-dying-by-age-5-per-1000-live-births))
622 [rate-\(probability-of-dying-by-age-5-per-1000-live-births\)](https://www.who.int/data/gho/data/indicators/indicator-details/GHO/under-five-mortality-rate-(probability-of-dying-by-age-5-per-1000-live-births)) (2021).
- 623 [63] Mortality among children aged 5-14 years, [https://www.who.int/news-room/fact-](https://www.who.int/news-room/fact-sheets/detail/mortality-among-children-aged-5-14-years)
624 [sheets/detail/mortality-among-children-aged-5-14-years](https://www.who.int/news-room/fact-sheets/detail/mortality-among-children-aged-5-14-years) (2019).
- 625 [64] Figure 1.9 Sex ratio at birth, 19822017, [https://www.unicef.cn/en/figure-19-sex-ratio-birth-](https://www.unicef.cn/en/figure-19-sex-ratio-birth-19822017)
626 [19822017](https://www.unicef.cn/en/figure-19-sex-ratio-birth-19822017) (2018).
- 627 [65] Tabulation on the 2010 Population Census of China,
628 <http://www.stats.gov.cn/tjsj/pcsj/rkpc/6rp/indexch.htm> (2011).
- 629 [66] P. J. Woestenberg, A. J. King, M. A. van der Sande, R. Donken, S. Leussink, F. R. van der
630 Klis, C. J. Hoebe, J. A. Bogaards, B. H. van Benthem, D. Adema, et al., No evidence for
631 cross-protection of the HPV-16/18 vaccine against HPV-6/11 positivity in female STI clinic
632 visitors, *Journal of Infection* 74 (4) (2017) 393–400.

Table 1: Description of variables and parameters.

Symbol	Description	Baseline	Unit	Range	Source
Subscripts					
f	Female				
m	Male				
k	Gender ($k = f, m$)				
Variables					
$S_k(t)$	Susceptible population of gender k				
$V_k(t)$	Vaccinated population of gender k				
$I_k(t)$	Infected population of gender k				
$N_k(t)$	Total size of population of gender k				
$N(t)$	Total size of population				
λ_k	Force of infection for gender k				
Parameters					
Λ_f	Recruits into sexually active females	340998	person/year	[317422,391244]	See text
Λ_m	Recruits into sexually active males	387463	person/year	[342579,428756]	See text
μ_f (μ_m)	Exit rate from sexually active females (males)	1/(55-15)	1/year	See text	
β_{mf}	Transmission rate from males to females	Calibration	1/year	Calibration	See text
β_{fm}	Transmission rate from females to males	Calibration	1/year	Calibration	See text
δ_f	Recovery rate from infection for females	12/12.3	1/year	[12/13.3,12/7.7]	See text
δ_m	Recovery rate from infection for males	12/6.5	1/year	[12/7.7,12/6.2]	See text
τ	Degree of protection by vaccine	0.899	none	[0.817,0.944]	[53]
ϕ_k	Percentage of new recruits vaccinated for gender k	varied	none		
v	Amount of vaccines per year ($v = \sum_k \phi_k \Lambda_k$)	varied	person/year		
<i>dummy</i>	Parameter for comparison in the PRCC	1	none	[1, 10]	See text

Table 2: Calibration for β_{mf} and β_{fm} and the corresponding R_0 for different HPV types in people aged 15-55 in Guangxi.

HPV types	p_f	p_m	δ_f	δ_m	β_{mf}	β_{fm}	R_0
HPV 16/18	107/2344	30/1937	12/12.3	12/6.5	2.8693	0.6967	1.0333
HPV 6/11	32/2344	23/1937	12/6.7	12/6.4	1.9637	1.8068	1.0140
HPV 31	0.8%	0.2%	12/6.5	12/6.9	6.999	0.4775	1.0062
HPV 33	0.9%	0.4%	12/11.7	12/6.1	2.2147	0.9603	1.008
HPV 45	0.4%	0.5%	12/6.7	12/6.7	1.3532	2.4648	1.0056
HPV 52	6.6%	1.5%	12/13.1	12/6.9	4.1167	0.4398	1.0443
HPV 58	3.5%	3.5%	12/12.7	12/6.4	0.9333	2.1271	1.0379

Table 3: PRCCs for R_0 and prevalences in females, males and the total population (* means significant).

Inputs	PRCC (R_0)	PRCC ($\frac{I_f}{N_f}$)	PRCC ($\frac{I_m}{N_m}$)	PRCC ($\frac{I_f + I_m}{N}$)
dummy	-0.0090	-0.0060	-0.0061	-0.0068
ϕ_m	-0.9244*	-0.9004*	-0.9043*	-0.9027*
ϕ_f	-0.9241*	-0.9042*	-0.8975*	-0.9038*
τ	-0.4139	-0.3508	-0.3481	-0.3528
δ_m	-0.2695	-0.7337*	-0.7369*	-0.7376*
δ_f	-0.5623*	-0.9486*	-0.9454*	-0.9486*
β_{fm}	0.2712	0.6596*	0.6619*	0.6634*
β_{mf}	0.5599*	0.9190*	0.9144*	0.9191*
μ	0.0010	0.0139	0.0130	0.0133*
Λ_f		-0.1156	-0.1425	-0.1297
Λ_m		-0.1308	-0.1027	-0.1182

Table 4: Time and total vaccines needed to reduce the prevalence in the total population to below 0.0005 given fixed vaccine amount every year. All vaccines are given to females. The following vaccine coverage refers to the coverage of 15-year-old girls per year.

Vaccines (per year)	Vaccine coverage	Time (year)	Total vaccines
50000	$\phi_f=0.15$	0-127.3598	6367990
60000	$\phi_f=0.18$	0-103.4169	6205014
70000	$\phi_f=0.21$	0-88.6719	6207033
80000	$\phi_f=0.23$	0-78.2606	6260848
90000	$\phi_f=0.26$	0-70.6311	6356799
100000	$\phi_f=0.29$	0-64.6396	6463960
110000	$\phi_f=0.32$	0-59.8739	6586129
120000	$\phi_f=0.35$	0-55.9049	6708588
130000	$\phi_f=0.38$	0-52.5262	6828460
140000	$\phi_f=0.41$	0-49.8603	6980442
150000	$\phi_f=0.44$	0-47.3095	7096425

Table 5: Time and total vaccines needed to reduce the prevalence in the total population to below 0.0005 given different vaccination strategies. All vaccines are given to females. The following vaccine coverage refers to the coverage of 15-year-old girls per year.

Vaccines (per year)	Vaccine coverage	Time (year)	Total vaccines
60000	$\phi_f=0.18$	0-103.4169	6205014
80000	$\phi_f=0.23$	0-50	5711221
40000	$\phi_f=0.12$	51-92.78052	
100000	$\phi_f=0.29$	0-30	
65000	$\phi_f=0.19$	31-60	5555080
30000	$\phi_f=0.09$	61-80.16933	
120000	$\phi_f=0.35$	0-20	
90000	$\phi_f=0.26$	21-40	5663935
60000	$\phi_f=0.18$	41-60	
30000	$\phi_f=0.09$	61-68.79783	

Table 6: Some vaccination strategies with total time less than 68 years and total vaccines less than 5.5 million in order to reduce the prevalence in the total population to below 0.0005. All vaccines are given to females. The following vaccine coverage refers to the coverage of 15-year-old girls per year. The integer $n = 1, 2, \dots$ represents the number of period.

Period length (year)	Vaccines in the first period (per year)	Vaccine deduction	vaccine coverage	Total time (year)	Total vaccines
10	150000	25000	$\phi_f=0.44-0.07n$	67.125	5250000
5	175000	15000	$\phi_f=0.51-0.04n$	58.0625	5225000
2	178000	6000	$\phi_f=0.52-0.02n$	59.225	5382950

Table 7: The values of R_0 with different vaccine distributions.

ϕ_f	ϕ_m	R_0
0	0	1.0333
0.25	0	0.9098
	0.125	0.8572
	0.25	0.8011
0.5	0	0.7667
	0.25	0.675
	0.5	0.5688
0.75	0	0.5897
	0.375	0.4802
	0.75	0.3366
1	0	0.3284
	0.5	0.2436
	1	0.1044

Table 8: Estimation of the numbers of 14-year-old girls and boys in 2021-2033 from newborns in 2007-2019*.

Year	Newborn	U5MR	Sex ratio (newborn)	Year	14-year children	Sex ratio (age 14)	14-year girls	14-year boys
2007	710000	15.77	120.68	2021	696787.9	117.376	326623	383377
2008	720000	13.4	121.12	2022	708615.4	117.816	330554	389446
2009	720000	11.22	121.56	2023	710467.5	118.256	329888	390112
2010	720000	10.88	122	2024	710756.4	118.696	329224	390776
2011	710000	9.7	120.4	2025	701873.3	117.096	327044	382956
2012	740000	7.89	118.8	2026	733110.5	115.496	343394	396606
2013	750000	7.73	117.2	2027	743159	113.896	350638	399362
2014	720000	7.74	115.6	2028	713424.1	112.296	339149	380851
2015	720000	6.25	114	2029	714690	110.696	341725	378275
2016	770000	6.03	113.446	2030	764521.1	110.142	366419	403581
2017	820000	4.99	112.892	2031	815171.7	109.588	391244	428756
2018	710000	4.98	112.338	2032	705827.8	109.034	339658	370342
2019	660000	4.77	111.23	2033	656285.1	107.926	317421	342579

*U5MR: under 5 mortality rate; Sex ratio: male/female (female is 100); The number of 14-year children is derived from the number of newborn and U5MR; Sex ratio at age 14 is derived from sex ratio at newborn; Numbers of 14-years girls and boys are derived from the number of 14-year children and the sex ratio at age 14 (for details see Appendix H).




Figure 1: Flow diagram of the model of HPV infection with vaccination. Each group (females and males, denoted by f and m , respectively) is divided into three subgroups: susceptible, infected and vaccinated, denoted by S , I and V , respectively. The transmission happens between females and males. Descriptions of parameters are given in Table 1.




Figure 2: The recruits to susceptible for Guangxi Province. We use data from Liuzhou for parameter calibration and apply to Guangxi. We assume that 14-year-old children are vaccinated and estimate the target population size in 2021-2033 by newborns in 2007-2019.




Figure 3: Sensitivity analysis using PRCC. In all panels, we choose 0.08, 0.01 as base values for ϕ_f and ϕ_m , respectively, and $[0.01, 0.99]$ as their range. We fix $\mu_f = \mu_m = \mu = 1/(55 - 15)$. The other parameters are from Table 1. The initial conditions for (b)-(d) are the pre-vaccination endemic equilibria and the end of time is 50 years.




Figure 4: (a) The basic reproduction number R_0 with different vaccine distributions. (b) The minimum vaccine amount v needed per year to achieve $R_0 = 1$ using linear programming. (c) R_0 for $v = 25000$. The vaccination proportion for males ϕ_m can be calculated according to the vaccine amount v and vaccination proportion for females ϕ_f . (d-f) Prevalences in females, males and the total population with different vaccine distributions for $v = 25000$. The other parameters are from Table 1. The initial conditions for (d-f) are the pre-vaccination endemic equilibria. It shows minimum R_0 is attained when all vaccines are given to girls, which results in lower prevalences in females, males and the total population.




Figure 5: (a) The basic reproduction number R_0 for different vaccine amount v . The vaccination proportion for males ϕ_m can be calculated according to v and the vaccination proportion for females ϕ_f . It shows $\min R_0$ is always attained when girls are vaccinated firstly. (b)-(f) Prevalences in the total population with different vaccine distributions for $v = 50000$, $v = 100000$, $v = 150000$, $v = 250000$, $v = 400000$. The other parameters are from Table 1. The initial conditions for (b)-(f) are the pre-vaccination endemic equilibria.

It is made available under a [CC-BY-ND 4.0 International license](https://creativecommons.org/licenses/by-nd/4.0/).




Figure 6: (a) Prevalences in the total population for different vaccine amount v assuming vaccinating girls firstly. All vaccines are given to females. The vaccine coverage can be found in Table 4. The other parameters are from Table 1. The initial conditions are the pre-vaccination endemic equilibria. (b) Zoomed figure of the lower part of panel (a).




Figure 7: (a) Prevalences in the total population with variable vaccination strategies assuming vaccinating girls firstly. (b) Prevalences in the total population for different HPV types if we allocate vaccine amount $v = 175000$ initially and reduce by 15000 every 5 years assuming vaccinating girls firstly and using bivalent vaccines. According to ref. [53, 66], we let the degree of protection τ for HPV 6/11, 31, 33, 45, 52 and 58 be 0, 0.5, 0.257, 0.91, 0.372 and 0.309, respectively. In the two panels, all vaccines are given to females. The vaccine coverage can be found in Table 5 and Table 6, respectively. The other parameters are from Table 1. The initial conditions are the pre-vaccination endemic equilibria.




Figure 8: (a) Prevalences in the total population for different vaccination strategies. (b) Prevalences in the total population for different catch-up vaccination proportions with all girls vaccinated by age 15 ($\phi_f = 1, \phi_m = 0$). The other parameters are from Table 1 and the initial conditions are the pre-vaccination endemic equilibria.